National Emerging Infectious Diseases Laboratories Operations
Project Number5UC7AI095321-11
Former Number5UC7AI095321-07
Contact PI/Project LeaderSULLIVAN, NANCY JEAN
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
Overall
Abstract
The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging
Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston
University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program,
the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's
missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious
diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To
provide training in these areas of research and to support a national response in the event of a biodefense
emergency; and (3) To establish a research facility with the highest attention to community and laboratory
safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and
develop a cadre of investigators and research staff with expertise in the scientific disciplines required to
investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including
collaborations within the university, in the United States, and internationally; (2) Develop animal models for the
comparative study of these pathogens, mimicking as closely as possible the human disease process, and build
capacity for the creation and use of relevant animal models and innovative veterinary research support; (3)
Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies
needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5)
Train the next generation of research scientists and related support personnel in the requirements to perform
maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to
support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment
for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in
2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and
complement existing expertise, bring innovative new insights and methodology to expand our scientific
capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL
has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well-
Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty
investigators, and as a result we also continue to evolve our integrated research support services to provide
support needed for BSL-4 research to better reflect and provide access to new technology and research
approaches, in order to remain at the leading edge of science.
Public Health Relevance Statement
Project Narrative
Newly emerging and re-emerging infectious diseases represent continuing threats to human health, both
nationally and globally. To improve our ability to diagnose, treat and prevent these potentially pandemic
pathogens, we must understand their biology and pathogenic mechanisms in order to develop the tools we
need. The mission of the NEIDL is to conduct this basic and translational research in a safe and secure
environment, and through our research and collaborations accelerate the research and development of
diagnostics, therapeutics, and vaccines for known and still to be identified emerging microbial threats.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-June-2014
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$11,500,000
Direct Costs
$9,781,355
Indirect Costs
$2,081,036
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$11,500,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5UC7AI095321-11
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5UC7AI095321-11
Patents
No Patents information available for 5UC7AI095321-11
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5UC7AI095321-11
Clinical Studies
No Clinical Studies information available for 5UC7AI095321-11
News and More
Related News Releases
No news release information available for 5UC7AI095321-11
History
No Historical information available for 5UC7AI095321-11
Similar Projects
No Similar Projects information available for 5UC7AI095321-11